제품 > 항체 > Biosimilar Antibody

Human CD38 Monoclonal Antibody (YR0007)

Direct ELISA binding curve demonstrating the recognition of Human Anti-Human CD38 (Research Grade Daratumumab Biosimilar) Monoclonal Antibody to CD38. The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.

ABclonal:Flow CytoMetry - Human CD38 Monoclonal Antibody (YR0007)

Detection of CD38 in Human PBMCs cell line by Flow Cytometry. Human PBMCs cell line was stained with Biotinylated Human Anti-Human CD38 (Daratumumab Biosimilar) Monoclonal Antibody followed by APC conjugated NeutrAvidin Secondary Antibody, or unstained cells (open blue histogram).

Basic Information

Clone	Daratumumab Biosimilar
Molecular Weight	150 kDa
Endotoxin	<1EU/mg (<0.001EU/μg)Determined by LAL gel clotting assay
Sterility	0.2 μm filtration
Aggregation	<5% Determined by SECP
Purity	>95% Determined by SEC-HPLC

Product Information

Production	Purified from cell culture supernatant in an animal-free facility
Purification	Protein A or G purification
Storage	2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Target Background

Daratumumab Biosimilar uses the same protein sequences as the therapeutic antibody daratumumab.Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody. Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.

Immunogen Information

Isotype	human IgG1 kappa
Immunogen	Human CD38
RecommendedIsotype Control(s)	In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody
Recommended Dilution Buffer	1×PBS pH 7.0